What Modafinil-Acino Treats: Main Uses and Benefits

The primary therapeutic role of Modafinil-Acino plays a role in managing pathologically Excessive Daytime Sleepiness (EDS), a symptom that creates noticeable physiological strain and interferes with daily functioning. The medication is commonly used to help with maintaining wakefulness in conditions where symptoms may intensify temporarily or chronic sleepiness is a defining characteristic.

The medication is applied in addressing core symptoms in specific chronic conditions, including narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) when residual sleepiness persists, and Shift Work Sleep Disorder (SWSD). This assistance provides supportive relief when symptoms interfere with routine activities and supports general well-being. “The application of this agent is commonly used across domains where additional symptomatic support is needed.”

Quick Fact: Symptomatic Support for Excessive Sleepiness

Quick Fact: Symptomatic Support for Excessive Daytime Sleepiness (EDS)

Modafinil-Acino is considered relevant in clinical scenarios involving chronic circadian disruption, such as SWSD, and when groups of symptoms, like residual sleepiness, persist in conditions where functional stability becomes affected. This supportive benefit contributes to easing the overall symptom load.

Regulatory References

1. NIH MedlinePlus overview of Modafinil

Who Can and Cannot Use Modafinil-Acino?

Eligibility for Modafinil-Acino is determined by official regulatory documents based on a patient's medical history and physiological status. The medicine is primarily indicated for use in adults diagnosed with excessive sleepiness associated with narcolepsy.

Absolute Non-Eligibility (Contraindications)

Modafinil-Acino is contraindicated and must not be used by specific populations due to labeled risk factors. This includes patients with known hypersensitivity to modafinil or armodafinil. Use is also strictly prohibited in individuals with existing uncontrolled moderate to severe hypertension or cardiac arrhythmias.

Age and Physiological Restrictions

• Pediatric Population: The medicine is not recommended or contraindicated for use in children and adolescents under 18 years of age as safety and effectiveness have not been established.
• Older Adults: Use in patients over 65 years is permitted but requires consideration of a lower starting dose due to the potential for reduced drug clearance.
• Pregnancy and Lactation: The medicine is contraindicated during both pregnancy and breastfeeding. Women of childbearing potential are required to use alternative, effective non-hormonal contraception during treatment and for two months after discontinuation.

Conditional Use

Patients with severe hepatic impairment (liver problems) require a mandatory reduction of the dosage by half. Caution and specialized monitoring are also required for patients with a history of certain psychiatric disorders, including psychosis or severe anxiety.

Interactions with other medicines and products

Modafinil has documented interactions with several categories of medicinal products, primarily due to its effects on drug-metabolizing enzymes in the liver.

Key Interaction Domains and Practical Constraints:

Interacting Product Category	Mechanistic Effect	Practical Constraint
Steroidal Contraceptives (e.g., oral, implantable)	Induction of the CYP3A4/5 enzyme.	Requires use of non-hormonal or alternative contraceptive methods during treatment and for two months after discontinuation.
Oral Anticoagulants (e.g., Warfarin)	Potential suppression of the CYP2C9 enzyme.	Requires regular monitoring of prothrombin times, particularly at the start of therapy and following dose changes.
CYP2C19 Substrates (e.g., Diazepam, Phenytoin, Propranolol)	Inhibition of the CYP2C19 enzyme.	May increase the exposure to the co-administered drug, potentially requiring a dose reduction of the co-administered drug.
CYP3A4/5 Substrates (e.g., Ciclosporin, Midazolam, Triazolam)	Induction of the CYP3A4/5 enzyme.	May decrease the exposure and effectiveness of the co-administered drug.

Official Interaction Profile Summary

The regulatory interaction profile emphasizes that co-administration can significantly alter the exposure of other medicines. Modafinil may increase or decrease the levels of co-administered drugs by inhibiting or inducing specific Cytochrome P450 enzymes. The documented consequences range from the need for mandatory alternative contraception (due to reduced effectiveness of hormonal methods) to the requirement for therapeutic monitoring for narrow therapeutic index medicines like Warfarin and Phenytoin. Patients must be carefully monitored when initiating, changing the dose of, or discontinuing modafinil while taking these interacting agents.

Selective Modulation of Catecholamine and Hypothalamic Systems

Modafinil's mechanism involves increasing the functional activity of the brain's arousal pathways. It achieves this by weakly and selectively binding to the Dopamine Transporter (DAT), slowing the reuptake of Dopamine, thereby increasing its availability, which contributes to increased functional tone in areas regulating wakefulness. This action also indirectly activates the Orexin (Hypocretin) and Histamine pathways, which are key physiological regulators of sustained wakefulness in the hypothalamus.

---

Coordinated Wakefulness Drive and Inhibitory Attenuation

This multi-pathway engagement results in a selective change in physiological status. The molecule also attenuates inhibitory signaling, specifically by reducing the release of GABA in key brain regions that govern sleep initiation. This reduction in GABA-mediated input allows the enhanced Dopaminergic, Histaminergic, and Orexinergic signals to dominate, shifting the Central Nervous System's functional balance toward a state of sustained central nervous system arousal.

How to Use Modafinil-Acino

Modafinil-Acino is a wakefulness-promoting agent administered exclusively via the oral route as a solid tablet. The drug is typically prescribed for long-term maintenance of wakefulness in adults with chronic sleep-related disorders, with dosing based strictly on regulatory guidelines. The medicine is taken once daily.

---

Dosing and Administration Logistics

The standard approach to using Modafinil involves specific dosage and timing instructions. The most common regimen is based on a 200 mg dose, with administration timing adjusted based on the specific condition being addressed.

Administration Detail	Official Guideline
Route	Oral (tablet swallowed whole with water).
Standard Starting Dose	200 mg once daily.
Maximum Daily Dose	400 mg.
Intake Condition	May be taken with or without food.

---

Timing and Specific Population Rules

The timing of the dose is critical for managing excessive daytime sleepiness and is determined by the patient’s intended sleep-wake cycle.

• Narcolepsy and OSAHS (Obstructive Sleep Apnea/Hypopnea Syndrome): The dose should be administered in the morning.
• Shift Work Sleep Disorder (SWSD): The dose should be taken approximately one hour prior to the start of the scheduled work shift.

For specific populations, dose adjustments are mandated by regulatory bodies. For example, the starting dose for patients with severe hepatic impairment is officially recommended to be halved to 100 mg per day. A reduced starting dose is also often advised for older adults to minimize potential issues with altered drug clearance.

---

These official instructions define the required procedural structure for administering the medicine, establishing the proper dosage limits and ensuring the administration is timed appropriately to support the intended period of wakefulness.

Modafinil-Acino: Recent Clinical Evidence

Study Outcomes and Measured Effects

Research has explored the effects of modafinil (the active substance in Modafinil-Acino) on excessive daytime sleepiness (EDS) associated with conditions like narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD).

Clinical trials, including randomized, double-blind, placebo-controlled studies, have measured the impact of the substance using objective and subjective scales.

• Objective Wakefulness: Studies using objective measures, such as the Maintenance of Wakefulness Test (MWT), have recorded an increased ability to stay awake during the day compared to placebo.
• Subjective Sleepiness: The severity of daytime sleepiness, as reported by patients on scales like the Epworth Sleepiness Scale (ESS), was shown to decrease in groups receiving the substance.

---

Dose and Administration Variables Studied

Research has examined the results of administering modafinil across different dosage levels (e.g., 200 mg and 400 mg daily). These studies found that effects on wakefulness and sleepiness were significant at both levels when compared to placebo, with some studies noting potential dose-dependent outcomes on specific measures.

• Timing: The impact of administration timing on outcomes has been a subject of study, with certain protocols noting the use of specific timings (such as morning dosing for narcolepsy) based on the target condition.

---

Adverse Events and Safety Profile

The profile of observed adverse events has been recorded across multiple trials in adult populations. In these trials, adverse events most frequently reported included headache, nausea, and nervousness.

• Comparison of Side Effects: In controlled trials, the overall incidence of side effects was similar across different modafinil dosages, though the 400 mg dose was sometimes associated with a higher occurrence of specific events compared to the 200 mg dose or placebo. The substance is generally noted to have a lower risk of dependence or rebound hypersomnia when compared to traditional central nervous system (CNS) stimulants.

Common questions about Modafinil-Acino (FAQ)

Q: How quickly does Modafinil-Acino start working after taking it?

A: According to official prescribing information, the medicine reaches its highest levels in the blood, known as peak plasma concentrations, approximately 2 to 4 hours after you take the dose. This time frame is when the maximum concentration of the drug is reached, which often corresponds to the peak wakefulness effect.

Q: How long does the effect of Modafinil-Acino last?

A: Studies on the drug’s elimination show that the average half-life of modafinil is about 10 to 12 hours. The long half-life supports once-daily dosing aimed at promoting wakefulness throughout the day.

Q: Is it normal to feel anxiety or jittery on Modafinil-Acino?

A: Regulatory documents indicate that feeling anxious is listed as a common side effect of the active substance modafinil. Additionally, other common side effects like palpitations (a racing heartbeat) and tachycardia (an abnormally fast heart rate) are reported, which may be experienced as a 'jittery' or restless feeling.

Q: Will I experience a crash or tiredness when Modafinil-Acino wears off?

A: Modafinil is classified as a wakefulness-promoting agent rather than a generalized psychomotor stimulant. Official clinical trial data indicates a lower risk of 'rebound hypersomnia,' or a sudden return of extreme sleepiness, when compared to classic Central Nervous System (CNS) stimulants.

Q: Is it true that Modafinil-Acino can help with concentration?

A: The medication is indicated for improving wakefulness and mental vigilance in patients with excessive sleepiness. The intent of treatment is to support alertness and functioning during waking hours.

Q: What are the signs of taking too much Modafinil-Acino?

A: Signs of overdosage reported can include agitation, difficulty sleeping, confusion, diarrhea, and increases in heart rate or blood pressure. These symptoms are documented in the official regulatory information regarding overdosage.

Q: What is the difference between Modafinil-Acino and regular modafinil?

A: Modafinil-Acino is a specific brand name product containing the active substance modafinil. The primary differences lie in the specific inactive ingredients (excipients) used in the tablet formulation and the company that manufactures and markets the product, which in this case is Acino.

Q: Does Modafinil-Acino cause trouble sleeping at night?

A: The official safety information lists insomnia (difficulty sleeping) as a common side effect of modafinil. This is why the timing of administration is often specified by a healthcare provider, such as taking it in the morning, to help manage potential sleep disruption.

Q: How does Modafinil-Acino work in the brain to promote wakefulness?

A: Modafinil works by selectively targeting certain areas of the brain to increase alertness. It achieves this by affecting the reuptake of the chemical dopamine, and by activating key natural pathways like the histamine and orexin systems that regulate a sustained state of wakefulness.

Q: Is Modafinil-Acino likely to make me feel euphoric or 'high'?

A: Modafinil is classified as a Schedule IV controlled substance due to a potential for abuse. While common side effects include anxiety and nervousness, specific feelings of euphoria are not commonly reported side effects in the official safety documents.

Q: Why is Modafinil-Acino sometimes discussed in the context of shift work?

A: Modafinil is officially indicated for the treatment of excessive sleepiness associated with Shift Work Sleep Disorder (SWSD). This is a recognized condition where people who work nights or rotating shifts have chronic sleep disruption.

Q: Is it safe to drive while taking Modafinil-Acino?

A: Official product labeling warns that the drug may cause effects such as blurred vision, dizziness, or somnolence (drowsiness). The official product labeling warns that the presence of these side effects may impair the ability to drive or operate machinery.

Q: Is Modafinil-Acino recommended for someone who only has mild sleepiness?

A: The medication is specifically indicated for the treatment of excessive daytime sleepiness associated with diagnosed medical conditions, such as narcolepsy. The drug is not indicated for the management of general fatigue or mild sleepiness; it is reserved for specific, diagnosed sleep disorders.

Q: What are the ingredients in Modafinil-Acino besides the active drug?

A: The medication contains Modafinil as its active ingredient. In addition, the tablet formulation includes a number of inactive ingredients, known as excipients, that are necessary for the drug’s form and stability. These are fully listed in the official packaging leaflet for Modafinil-Acino.

Q: How is Modafinil-Acino metabolized in the liver?

A: Official studies indicate that modafinil is primarily metabolized, or broken down, in the liver. The major pathway involves a specific group of liver enzymes, primarily CYP3A4, before the resulting products are eliminated from the body, mostly through the kidneys.

Q: What is the risk of developing a skin rash from Modafinil-Acino?

A: Official safety warnings indicate that modafinil can, in rare cases, cause serious, life-threatening skin rashes, including Stevens-Johnson Syndrome (SJS). These reactions usually occur early in treatment. The regulatory guidance advises immediate discontinuation of the medication if a rash develops.

Q: What are the pharmacological properties that make Modafinil-Acino different from stimulants?

A: Modafinil belongs to the eugeroic class, promoting wakefulness through a mechanism distinct from classic psychomotor stimulants. Its pharmacological properties involve selective effects on arousal systems rather than generalized central nervous system excitement and widespread euphoric effects.

Q: Can I stop taking Modafinil-Acino suddenly, or do I need to taper off?

A: The drug is noted to have a low risk of dependence. However, sudden discontinuation may lead to withdrawal symptoms in some individuals. Changes to the drug regimen, including discontinuation, are clinical decisions that must be determined by a healthcare professional.

Q: Does Modafinil-Acino affect appetite or weight?

A: Official regulatory documents list anorexia (loss of appetite) and decreased appetite as common side effects of the medication. Changes in weight have also been reported as a common side effect in clinical trials.

Q: Does alcohol interact dangerously with Modafinil-Acino?

A: Yes, official safety information states that the consumption of alcohol should be avoided while taking this medicine. This is a standard precautionary measure listed in the product's safety profile.

Q: Is it possible to develop a tolerance to Modafinil-Acino over time?

A: Clinical trials did not show evidence of tolerance developing during the duration of those studies. However, the official prescribing information notes that the potential for tolerance developing with long-term use cannot be completely ruled out.

Q: What over-the-counter medicines should I avoid while taking Modafinil-Acino?

A: Modafinil can affect the way the body processes other medicines by influencing specific liver enzymes (CYP450 enzymes). It is essential that all medications, including non-prescription products, are reviewed by a healthcare provider for potential interactions.

Q: Are there any food or drink restrictions while on Modafinil-Acino?

A: Yes, official safety information advises that the consumption of alcohol should be avoided while taking this medication. The tablets themselves may be taken either with food or on an empty stomach.

How to Store and Dispose of Modafinil-Acino

Storage Conditions

Modafinil tablets must be stored at room temperature, within the specific range of 68 F to 77 F (20 C to 25 C). The medication must be kept in the container it came in, with the cap tightly closed and protected from excess heat, moisture, and light. To ensure child safety, the container must be kept out of the sight and reach of children and pets, with safety caps locked.

As a Schedule IV controlled substance, the medication must also be stored in a safe place to prevent theft.

Disposal Instructions

Unused or expired Modafinil-Acino should be disposed of by following official government guidelines. The preferred method is a drug take-back program. If a program is unavailable, the tablets should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash.